share_log

Nano X Imaging | 6-K: Report of foreign private issuer (related to financial reporting)

Nano X Imaging | 6-K: Report of foreign private issuer (related to financial reporting)

Nano X Imaging | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/11/21 13:09

牛牛AI助理已提取核心訊息

Nanox reported Q3 2024 revenue of $3.0 million, up from $2.5 million in Q3 2023, driven by growth in teleradiology services and AI solutions. The company posted a net loss of $13.6 million, an improvement from $21.4 million loss in the prior year period, primarily due to reduced impairment expenses.The company continued expanding its US sales and support teams while making progress in global deployment of Nanox.ARC systems. The Nanox.AI business secured new distribution agreements with SpinexMedical and extended partnerships with major healthcare providers including Corewell Health and Oxford University Hospitals.As of September 30, 2024, Nanox maintained a strong financial position with $57.1 million in cash, cash equivalents and marketable securities. The company is actively working with FDA on full body scanning approval and pursuing CE Mark designation in Europe, which management believes will significantly expand their addressable market.
Nanox reported Q3 2024 revenue of $3.0 million, up from $2.5 million in Q3 2023, driven by growth in teleradiology services and AI solutions. The company posted a net loss of $13.6 million, an improvement from $21.4 million loss in the prior year period, primarily due to reduced impairment expenses.The company continued expanding its US sales and support teams while making progress in global deployment of Nanox.ARC systems. The Nanox.AI business secured new distribution agreements with SpinexMedical and extended partnerships with major healthcare providers including Corewell Health and Oxford University Hospitals.As of September 30, 2024, Nanox maintained a strong financial position with $57.1 million in cash, cash equivalents and marketable securities. The company is actively working with FDA on full body scanning approval and pursuing CE Mark designation in Europe, which management believes will significantly expand their addressable market.
Nanox報告2024年第三季度營業收入爲300萬美元,較2023年第三季度的250萬美元增長,主要得益於遠程放射學服務和人工智能解決方案的增長。公司淨虧損爲1360萬美元,較去年同期的2140萬美元虧損有所改善,主要由於減值費用減少。公司繼續擴大其美國銷售和壓力位團隊,同時在全球部署Nanox.ARC系統方面取得進展。Nanox.AI業務與SpinexMedical簽署了新分銷協議,並與包括Corewell Health和牛津大學醫院在內的主要醫療保健提供商擴展了合作關係。截至2024年9月30日,Nanox保持強勁的財務狀況,現金、現金等價物及可交易證券總額爲5710萬美元。公司積極與FDA合作,申請全身掃描批准,並在歐洲尋求CE標記認證,管理層相信這將顯著擴大他們的可達市場。
Nanox報告2024年第三季度營業收入爲300萬美元,較2023年第三季度的250萬美元增長,主要得益於遠程放射學服務和人工智能解決方案的增長。公司淨虧損爲1360萬美元,較去年同期的2140萬美元虧損有所改善,主要由於減值費用減少。公司繼續擴大其美國銷售和壓力位團隊,同時在全球部署Nanox.ARC系統方面取得進展。Nanox.AI業務與SpinexMedical簽署了新分銷協議,並與包括Corewell Health和牛津大學醫院在內的主要醫療保健提供商擴展了合作關係。截至2024年9月30日,Nanox保持強勁的財務狀況,現金、現金等價物及可交易證券總額爲5710萬美元。公司積極與FDA合作,申請全身掃描批准,並在歐洲尋求CE標記認證,管理層相信這將顯著擴大他們的可達市場。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 987

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。